Bicycle Therapeutics (BCYC) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 45.9% versus a loss of 56.1%. Over five years, BCYC leads with a -93.4% price change compared with -96.5% for ZNTL. Bicycle Therapeutics is the larger company by market cap ($272.3 million vs $259.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | ZNTL |
|---|---|---|
| Share price | $3.89 | $2.64 |
| Market cap | $272.27M | $259.04M |
| 1-day change | +2.10% | +5.18% |
| YTD return | -45.06% | +95.56% |
| 1-year return | -56.14% | +45.86% |
| 5-year return | -93.44% | -96.48% |
| EPS (TTM) | $-2.73 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.08 | $6.95 |
| 52-week low | $3.33 | $1.21 |
| Distance from 52-week high | -57.16% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +144.22% | +177.65% |
| Average volume | 379.42K | 1.20M |
| Shares outstanding | 50.55M | 98.12M |
| Employees | 288 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed BCYC by 102.0 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
BCYC vs ZNTL FAQ
Which is bigger, Bicycle Therapeutics or Zentalis Pharmaceuticals?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $272.27M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, BCYC or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -56.14% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.